Trulicity (dulaglutide) / Eli Lilly - LARVOL DELTA

Weekly GLP-1 Receptor Agonists in Obese Individuals Without Diabetes (clinicaltrials.gov) - P3 | N=150 | Completed | Sponsor: Zagazig University

New P3 trial • Diabetes • Genetic Disorders • Metabolic Disorders • Obesity

GLP-1 receptor agonists and ocular safety- Pharmacokinetic insights into ischemic optic neuropathy and diabetic retinopathy risk: A review. (PubMed, Biomol Biomed) - "Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have transformed the management of type 2 diabetes mellitus and obesity, but their expanding use has raised concerns about ocular safety...The most consistent NAION signal involved high-exposure subcutaneous semaglutide, whereas findings for oral semaglutide, liraglutide, dulaglutide, exenatide, and tirzepatide were absent, inconsistent, or weaker...Semaglutide 7.2 mg, with an estimated Css of approximately 230 nmol/L, and highly bioavailable oral orforglipron warrant formulation-specific postmarketing ocular surveillance, although direct evidence of NAION risk remains unavailable. Current evidence does not support class-wide prescribing restrictions. An individualized approach considering patient-specific ocular risk, agent, formulation, and dose is more appropriate, while prospective studies with standardized ophthalmic endpoints are needed to establish causality and validate pharmacokinetic and pharmacogenomic..."

Journal • PK/PD data • Review • Diabetes • Diabetic Neuropathy • Diabetic Retinopathy • Genetic Disorders • Metabolic Disorders • Obesity • Ocular Inflammation • Ophthalmology • Optic Neuritis • Pain • Retinal Disorders • Type 2 Diabetes Mellitus

Real-World Impact of Weekly Dulaglutide and Semaglutide on Hba1c and Weight in a Predominantly Underrepresented Demographic. (PubMed, J Health Care Poor Underserved) - "Weekly dulaglutide and semaglutide significantly reduced HbA1c and weight. Further research is needed to explore factors influencing differential responses."

Journal • Real-world evidence • Retrospective data • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Exit Interviews Examining Patient Experiences with Tirzepatide and Dulaglutide for Treatment of Type 2 Diabetes in the SURPASS-CVOT Trial. (PubMed, Diabetes Ther) - "Exit interview results indicate that self-reported treatment benefits were important to people who received long-term treatment with dulaglutide or tirzepatide."

Interview • Journal • Atherosclerosis • Cardiovascular • Diabetes • Immunology • Metabolic Disorders • Musculoskeletal Diseases • Musculoskeletal Pain • Obstructive Sleep Apnea • Orthopedics • Osteoarthritis • Pain • Respiratory Diseases • Rheumatology • Sleep Apnea • Sleep Disorder • Type 2 Diabetes Mellitus

The differential effects of GLP-1 based therapies in airways disease (ERS 2026) - "No associations were observed for liraglutide, dulaglutide, or exenatide, irrespective of dose or underlying lung disease. Associations were substantially stronger in asthma than in COPD. Asthma comorbidity may guide GLP-1RA selection in diabetes and obesity management."

Asthma • Chronic Obstructive Pulmonary Disease • Diabetes • Genetic Disorders • Immunology • Metabolic Disorders • Obesity • Pulmonary Disease • Respiratory Diseases • Type 2 Diabetes Mellitus

GLP-1RA Use and Sleep Apnea Outcomes: A Database Study and Systematic Review (AAO-HNSF 2026) - "A multicenter, retrospective cohort study was conducted via the TriNetX database to assess adults in the United States with obesity and/or type 2 diabetes, stratified by GLP-1RA exposure (dulaglutide, exenatide, semaglutide, liraglutide). GLP-1RA exposure was associated with reduced incident OSA, OSA-related testing, and treatment escalation, supporting a potential role of GLP-1RA therapy as an adjunct in OSA management. Increased continuation codes and individual medication differences highlight a need for prospective studies to clarify causal effects."

Review • Diabetes • Genetic Disorders • Metabolic Disorders • Obesity • Obstructive Sleep Apnea • Respiratory Diseases • Sleep Apnea • Sleep Disorder • Type 2 Diabetes Mellitus

The Impact of GLP-1 Medications and the Development of Patulous Eustachian Tube Dysfunction (AAO-HNSF 2026) - "392,953 patients aged ≥18 with an overweight or obese diagnosis (ICD-10-CM: E66) prescribed GLP-1 medication (exenatide, tirzepatide, lixisenatide, semaglutide, liraglutide, or dulaglutide) we identified between 1/1/2022 and 1/1/2025. GLP-1-based treatments were significantly associated with the development of PETD and any ETD. General providers and hearing specialists should be aware of this potential risk when managing patients who take GLP-1-related medications."

Allergic Rhinitis • Asthma • Genetic Disorders • Immunology • Inflammation • Obesity • Otorhinolaryngology • Respiratory Diseases • Sinusitis

Do GLP-1 Receptor Agonists Increase Thyroid Cancer Risk? Reassuring Evidence from over Two Million Patients (AAO-HNSF 2026) - "Introduction: Use of glucagon-like peptide-1 receptor agonists (GLP1RA) has rapidly expanded due to benefits in glycemic control, weight loss, and cardiovascular risk reduction...GLP1RA medications included dulaglutide, exenatide, lixisenatide, liraglutide, semaglutide, and tirzepatide... This is the largest study in the US evaluating thyroid cancer risk in the GLP1RA user population. There were few incident thyroid cancer cases and no overall increased risk of incident thyroid cancer compared with non-users."

Clinical • Oncology • Solid Tumor • Thyroid Gland Carcinoma

Nutritional Deficiencies, Complications, and Nutrition Therapy/Counseling in Pediatric Patients Using GLP-1 Receptor Agonists. (PubMed, Child Obes) - "Nutritional deficiencies are a meaningful and under-recognized risk among pediatric patients receiving GLP-1RA therapy. Current care patterns suggest missed opportunities for proactive and preventative nutrition support. Integration of NT/C care into pediatric GLP-1RA treatment may support healthy growth and long-term outcomes."

Journal • Genetic Disorders • Hematological Disorders • Metabolic Disorders • Obesity • Pediatrics • Type 2 Diabetes Mellitus

Sustained weight loss exceeding 100 kg with sequential incretin-based therapy in Prader-Willi syndrome. (PubMed, JCEM Case Rep) - "He received sequential incretin-based therapy, initiated with retatrutide (1-12 mg weekly) within a clinical trial, followed by oral semaglutide and then dulaglutide after retatrutide became unavailable, together with a structured hypocaloric diet and supervised exercise. Mild transient gastrointestinal symptoms occurred during dose escalation, with no serious adverse events. Follow-up bioimpedance showed a skeletal muscle mass of 38.5 kg after a 58.8% reduction in total body weight."

Journal • Diabetes • Endocrine Disorders • Genetic Disorders • Metabolic Disorders • Obesity • Prader–Willi syndrome • Type 2 Diabetes Mellitus

Hidden Interaction: Dulaglutide Significantly Alters Immunosuppressant Pharmacokinetics After Kidney Transplantation (TTS 2026) - "It is crucial to characterise the impact of these agents on the pharmacokinetics (PK) of tacrolimus (TAC) and mycophenolate mofetil and given its narrow therapeutic window, the large interpatient variability, its interaction with other drugs and its impact on allograft outcomes. The PK profile of MMF/TAC shows lower AUC when dulaglutide is used in KT recipients. Caution must be taken when initiating GLP1RA in transplant recipients, with an increase in the dose of immunosuppressants being necessary in order to avoid allograft rejection."

PK/PD data • Diabetes • Metabolic Disorders • Transplant Rejection • Transplantation

An elderly patient with type 2 diabetes who developed a hyperglycemic emergency and showed a marked decline in insulin secretion, but she was able to be weaned off insulin by alleviating glucose toxicity and adjusting her medication: A case report (PubMed, Nihon Ronen Igakkai Zasshi) - "After initiating dulaglutide and repaglinide treatment, insulin therapy, which peaked at 23 units/day, was discontinued. Although insulin withdrawal was predicted to be challenging based on previous reports, it was successfully performed in the present case. This case represents a suggestive example that highlights the relevant considerations for evaluating the residual insulin secretory function."

Journal • CNS Disorders • Dermatology • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Comparative Study of Different Weekly GLP-1 Receptor Agonists Among Diabetic and Non-Diabetic Patients: Clinical Trial (clinicaltrials.gov) - P3 | N=159 | Completed | Sponsor: Zagazig University

New P3 trial • Metabolic Disorders • Obesity

GLP-1 Receptor Agonists and Musculoskeletal Outcomes: A Systematic Literature Review and Meta-Analysis. (PubMed, Drugs) - "This meta-analysis is the first to investigate the effects of GLP-1 RAs on a large panel of musculoskeletal health outcomes. While no significant effects were observed on bone- or joint-related outcomes, GLP-1 RAs were associated with reductions in lean body mass/fat-free mass, although the certainty of evidence was low and these changes appeared largely related to weight loss. Whether these changes translate into clinically meaningful impairments in muscle function or physical performance remains uncertain. Further studies in this field, including those looking at muscle function, strength or performance and using multivariate models considering confounding are needed to better reinforce the models and final findings."

Journal • Retrospective data • Review • Diabetes • Genetic Disorders • Immunology • Metabolic Disorders • Musculoskeletal Diseases • Obesity • Orthopedics • Osteoarthritis • Pain • Rheumatology • Type 2 Diabetes Mellitus

Weight regain following discontinuation of glucagon-like peptide-1 receptor agonists in adults who are overweight or obese: a systematic review and meta-analysis. (PubMed, PeerJ) - "Collect randomised controlled trials (RCTs) and controlled trials on GLP-1RAs, including tirzepatide, semaglutide, liraglutide, and dulaglutide, for the treatment of overweight or obese adult patients. There is a significant weight rebound phenomenon after discontinuation of GLP-1RAs, and the rebound magnitudes vary among different types of drugs. At the same time, there is a risk of adverse reactions during the use of such drugs."

Clinical • Journal • Retrospective data • Review • Cardiovascular • Obesity

Assessing the Association Between GLP-1 Receptor Agonists and Diabetic Foot Complications Using Real-World Pharmacovigilance Database and Mendelian Randomization. (PubMed, Int J Low Extrem Wounds) - "This trend was consistently observed across individual GLP-1RA molecules, including semaglutide (PRR, 0.45; 95% CI, 0.39 to 0.51), dulaglutide (PRR, 0.49; 95% CI, 0.45 to 0.54), and liraglutide (PRR, 0.30; 95% CI, 0.26 to 0.35). These results remained robust after conducting secondary and sensitivity analyses, further supporting their consistency and reliability. MR results generally corroborated the findings from the retrospective analyses of the AE records in the FAERS database.ConclusionsPharmacovigilance and drug target MR suggested a potential association between GLP-1RA use and diabetic foot complications, but the evidence is preliminary and requires further real-world prospective validation."

Adverse events • Journal • Real-world evidence • Diabetes

GLP-1/GIP Receptor Agonists in Obesity-Related HFpEF: The GLIDE-HF Registry (clinicaltrials.gov) - P=N/A | N=150 | Not yet recruiting | Sponsor: Miedziowe Centrum Zdrowia SA

New trial • Cardiovascular • Congestive Heart Failure • Genetic Disorders • Heart Failure • Hematological Disorders • Hypertension • Obesity • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases

Trends in Endoscopic Sleeve Gastroplasty Utilisation Among Patients With Obesity, Overweight, and Diabetes: A Multi-Institutional Retrospective Analysis Over 5 Years (ACG 2026) - "GLP-1 RA use post ESG was dominated by semaglutide (8%), liraglutide (4%), dulaglutide (4%) and tirzepatide (2%) as in table 2... A total of 5,201 patients with DM, Obesity and overweight underwent ESG which was predominantly utilized by middle-aged White, non-Hispanic females with mean age around 56 years. ESG recipients demonstrated a substantial burden of cardiometabolic disease, including diabetes, hypertension, ischemic heart disease and also GERD and Gastritis. Baseline characteristics and other associated comorbidities are described in table 1."

Retrospective data • Cardiovascular • Coronary Artery Disease • Diabetes • Gastroesophageal Reflux Disease • Gastrointestinal Disorder • Genetic Disorders • Heart Failure • Hypertension • Metabolic Disorders • Obesity

Postmarketing Safety Signals and Medication-Use Risks of GLP-1-Based Therapies in Diabetes and Obesity: A Multi-Source Pharmacovigilance and Regulatory Evidence-Mapping Study. (PubMed, Diabetes Obes Metab) - "Multi-source pharmacovigilance can improve interpretation of GLP-1 postmarketing safety evidence in diabetes and obesity care. Findings should be interpreted as signal-prioritisation and medication-safety evidence, not as incidence, proof of causality, or population-level comparative risk, given the limited clinical interpretability of spontaneous-reporting data."

Adverse events • Journal • P4 data • Diabetes • Genetic Disorders • Hypoglycemia • Metabolic Disorders • Obesity • Pain

Multi-Database Pharmacovigilance Analysis of Gastroesophageal Reflux Disease Associated with GLP-1 Receptor Agonists: A Cross-National Signal Validation Study. (PubMed, Gut Liver) - "Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are widely prescribed for type 2 diabetes and obesity...Drug-specific analyses revealed the strongest signals for semaglutide across all databases (3.44 to 6.93), followed by liraglutide (2.36 to 5.90), tirzepatide (2.76 to 5.77), and dulaglutide (2.35 to 3.32). Exenatide showed an inverse association in FAERS (ROR, 0.60; 95% CI, 0.46 to 0.77)...This first multi-database pharmacovigilance analysis confirms consistent GERD signals for GLP-1 RAs across Western and Asian populations, demonstrating approximately 2- to 5-fold higher reporting. Clinicians need to monitor for reflux symptoms during GLP-1 RA therapy, particularly in elderly patients."

Adverse events • Journal • Diabetes • Gastroenterology • Gastroesophageal Reflux Disease • Genetic Disorders • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus

Efficacy and safety of TG103 versus dulaglutide as an add-on to metformin in patients with type 2 diabetes: a randomised Phase III trial (EASD 2026) - P3 | "TG103 15 mg was noninferior to DULA in glycemic control with T2D on metformin. TG103 showed sustained glycemic improvement, with marked efficacy evident at week 8, stabilized at week 12, and maintained to week 52, as well as improvement trend in cardiometabolic markers and an overall favorable safety profile over 52 weeks. These findings suggest that TG103 15 mg is a promising add-on treatment option for this patient population."

Clinical • P3 data • Diabetes • Metabolic Disorders • Severe Hypoglycemia • Type 2 Diabetes Mellitus

Association Between GLP-1 Receptor Agonist Exposure and Acute Pancreatitis Risk in Patients With Cholelithiasis: A Real-World Cohort Study (ACG 2026) - "Introduction: GLP-1 receptor agonists (GLP-1 RAs) are widely used for type 2 diabetes and obesity...Adults (â¥18 years) with cholelithiasis who were exposed to GLP-1 RAs (semaglutide, dulaglutide, liraglutide, exenatide, tirzepatide) were compared to unexposed patients... 162,458 patients were included per cohort. For the primary outcome, 152,331 vs 151,712 patients were compared, and acute pancreatitis occurred in 2,172 (1.43%) vs 2,979 (1.96%) (RD -0.54%, 95% CI -0.63 to -0.45%; RR 0.73, 95% CI 0.69-0.76; HR 0.64, 95% CI 0.61-0.68; p< 0.001). 158,091 vs 158,395 patients were compared for the secondary outcome and gallstone pancreatitis occurred in 998 (0.63%) vs 1,745 (1.102%) (RD -0.47%, 95% CI -0.54 to -0.41%; RR 0.57, 95% CI 0.53-0.62; p< 0.001) (Table 1)."

Clinical • Real-world • Real-world evidence • Diabetes • Gastroenterology • Genetic Disorders • Metabolic Disorders • Obesity • Pancreatitis • Type 2 Diabetes Mellitus

Cardiovascular outcomes in older patients: a prespecified analysis of SURPASS-CVOT (EASD 2026) - P3 | "In the SURPASS-CVOT study, tirzepatide demonstrated comparable MACE outcomes, cardiometabolic effects, and safety profile to dulaglutide across a wide range of patient ages. Thus, tirzepatide may represent an appropriate treatment option for elderly patients with type 2 diabetes who are at increased cardiovascular risk."

Clinical • Diabetes • Hypoglycemia • Metabolic Disorders • Type 2 Diabetes Mellitus

Glucagon-Like Peptide-1 Receptor Agonists and the Risk of Colorectal Cancer Among Adults With Obesity: A Multicenter Real-World Cohort Study (ACG 2026) - "After matching,1,340,395 adults remained in each cohort achieving demographic balance(mean age 52 years; 66% female; 69% White,19% Black & 2% Asian).GLP-1RA exposure was associated with a 67.5% lower risk of composite CRC with significant reductions in CC(RR 0.495,95% CI 0.479â0.512) and RC(0.411,0.386â0.437).Associations remained significant in adults< 45 years with particularly pronounced reduction in RC(0.289, 0.214â0.389) & CC(0.428, 0.358â0.512).Findings were consistent across BMI strata and among individuals with concomitant obesity and diabetes.Drug-specific analyses with semaglutide,tirzepatide & dulaglutide demonstrated significant reductions in both CC and RC risk.Liraglutide was associated with lower RC risk, whereas no significant associations were observed with exenatide. Myopia, used as a negative control outcome demonstrated a near-null association In this large real-world cohort of adults with obesity, GLP-1RA use was..."

Clinical • Real-world • Real-world evidence • Colon Cancer • Colorectal Cancer • Diabetes • Genetic Disorders • Metabolic Disorders • Obesity • Oncology • Ophthalmology • Solid Tumor

XTL6001: a novel triple MasR/GCGR/GLP-1R agonist for chronic kidney disease/diabetic kidney disease with proteinuria and hyperuricaemia (EASD 2026) - P1 | "Within the tested dose range, the 24-hour urinary albumin reduction rates of XTL6001 were 55.85% to 81.85% (vs. 38.64% for Finerenone) in Model 1, 54.72% (vs. 32.49% for Finerenone combined with Dulaglutide) in Model 2, and 71.44% to 86.26% in Model 3 (uric acid-lowering medication benzbromarone had no effect on reducing urinary albumin), respectively. These findings indicated XTL6001 offers a multidimensional therapeutic solution for patients with CKD/DKD complicated by proteinuria and hyperuricemia by integrating renal protection and metabolic regulation. Thus, XTL6001 warrant further clinical assessment."

Metabolic Disorders